FIELD: chemistry.
SUBSTANCE: disclosed is a method of producing pure crystalline D-isoglutamyl-D-trytophan which involves a step of removing protection from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or diester thereof to yield essentially pure D-isoglutamyl-D- tryptophan. An amorphous ammonium alt of D-isoglutamyl-D- tryptophan (1:1) is also disclosed. Also disclosed is a method of producing a pure monoammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D- isoglutamyl-D-tryptophan. Disclosed is a compound H-D-Glu-(γ-D-Trp-OR2)-α-OR1
and pharmaceutically acceptable acid addition salts thereof. Disclosed is a solid pharmaceutical composition and use thereof as an immunodepressant or anti-psoriasis agent.
EFFECT: improved method.
51 cl, 14 ex, 8 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICALLY ACCEPTABLE THYMODEPRESSIN SALTS AND METHOD OF OBTAINING THEREOF | 2007 |
|
RU2536685C2 |
| METHOD OF PRODUCING MONOSODIUM SALT OF ISOGLUTAMYL-TRYPTOPHAN | 2019 |
|
RU2703991C1 |
| CRYSTALLINE FORMS OF MONOSODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | 2008 |
|
RU2476440C2 |
| PEPTIDE SHOWING IMMUNOSUPPRESSIVE PROPERTY | 1996 |
|
RU2123859C1 |
| AGENTS ENHANCING GROWTH HORMONE SECRETION | 2001 |
|
RU2270198C2 |
| AC-HIS-ALA-GLU-GLU-NH PEPTIDE PRODUCTION METHOD | 2021 |
|
RU2767030C1 |
| METHOD FOR LIQUID-PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | 2015 |
|
RU2694051C2 |
| LANTHIONINE DERIVATIVES | 2010 |
|
RU2518890C2 |
| NOVEL METHODS OF PRODUCING BARUSIBAN AND INTERMEDIATE COMPOUNDS THEREOF | 2016 |
|
RU2726414C2 |
| BIOGENIC AMINE N-ACYL DERIVATIVES ARE MODULATORS OF LIPID PEROXIDE OXIDATION, AND METHOD OF PREPARATION THEREOF | 1994 |
|
RU2093520C1 |
